Tags

Type your tag names separated by a space and hit enter

Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Orthop Surg. 2017 Feb; 9(1):103-109.OS

Abstract

OBJECTIVE

This randomized, double-blind, placebo-controlled study assessed the necessity of early intervention, safety and efficacy of intravenous zoledronic acid 5 mg/year in East China women with newly diagnosed osteoporosis at high risk of fracture during a 24-month treatment period.

METHODS

Subjects (57 [52-62] years old) were randomized 3:2 to zoledronic acid versus placebo (randomized at baseline, zoledronic acid [175 cases], placebo-zoledronic acid [110 cases]). The bone mineral density of the lumbar spine and total hip was measured every 6 months with the use of dual-energy X-ray absorptiometry. Serum procollagen I N-terminal pro-peptide (PINP) and serum C-telopeptide of type I collagen (CTX) levels were measured every 6 months. The primary end point was the rate of change in the bone mineral density at the posteroanterior spine.

RESULTS

For subjects with measurements at 24 months, zoledronic acid significantly increased bone mineral density (BMD) at the lumbar spine (mean percent change ± SD, zoledronic acid 5.390% ± 0.854% versus placebo-zoledronic acid -1.038% ± 0.599%), the total hip (zoledronic acid 1.900% ± 0.262% versus placebo-zoledronic acid -1.631% ± 0.649%). Serum procollagen I N-terminal pro-peptide (PINP) and CTX decreased rapidly with zoledronic acid 5 mg treatment (P < 0.001 versus placebo at 6 month and 24 months) and changed from baseline in the zoledronic acid 5 mg and placebo-zoledronic acid 5 mg at 6 months by a mean of -66.348% and -75.375%, respectively (P < 0.001), and at 24 months by -49.950% and -52.325%, respectively (P < 0.001). No cases of serious adverse events were observed in two groups. Headache, pyrexia and myalgia occurred more commonly within the first 3 days after infusion with zoledronic acid 5 mg than with placebo (13.7% versus 2.1%, P = 0.0018; 28.0% versus 3.2%, P < 0.001; 21.7% versus 4.2%, P < 0.001, respectively).

CONCLUSIONS

These data show that early application of zoledronic acid 5 mg/year was well stimulated and tolerated for bone mass in newly diagnosed east china subjects with osteoporosis in a 24-month treatment.

Authors+Show Affiliations

Department of Osteology, Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China. Department of Osteology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.Department of Osteology, Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.Department of Osteology, Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.Department of Osteology, Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.Department of Osteology, Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.Department of Osteology, Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.Department of Diagnostics of Traditional Chinese Medicine, College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.Department of Osteology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

28276638

Citation

Liang, Bo-Cheng, et al. "Intravenous Zoledronic Acid 5 Mg On Bone Turnover Markers and Bone Mineral Density in East China Subjects With Newly Diagnosed Osteoporosis: a 24-month Clinical Study." Orthopaedic Surgery, vol. 9, no. 1, 2017, pp. 103-109.
Liang BC, Shi ZY, Wang B, et al. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study. Orthop Surg. 2017;9(1):103-109.
Liang, B. C., Shi, Z. Y., Wang, B., Wu, P., Kong, L. C., Yao, J. L., Li, C. W., & Shi, X. L. (2017). Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study. Orthopaedic Surgery, 9(1), 103-109. https://doi.org/10.1111/os.12307
Liang BC, et al. Intravenous Zoledronic Acid 5 Mg On Bone Turnover Markers and Bone Mineral Density in East China Subjects With Newly Diagnosed Osteoporosis: a 24-month Clinical Study. Orthop Surg. 2017;9(1):103-109. PubMed PMID: 28276638.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study. AU - Liang,Bo-Cheng, AU - Shi,Zhen-Yu, AU - Wang,Bo, AU - Wu,Peng, AU - Kong,Ling-Cheng, AU - Yao,Jian-Liang, AU - Li,Chun-Wen, AU - Shi,Xiao-Lin, Y1 - 2017/03/09/ PY - 2016/06/20/received PY - 2016/06/29/accepted PY - 2017/3/10/pubmed PY - 2017/10/17/medline PY - 2017/3/10/entrez KW - Bone mineral density KW - Bone turnover markers KW - Early intervention KW - Placebo-controlled study KW - Zoledronic acid SP - 103 EP - 109 JF - Orthopaedic surgery JO - Orthop Surg VL - 9 IS - 1 N2 - OBJECTIVE: This randomized, double-blind, placebo-controlled study assessed the necessity of early intervention, safety and efficacy of intravenous zoledronic acid 5 mg/year in East China women with newly diagnosed osteoporosis at high risk of fracture during a 24-month treatment period. METHODS: Subjects (57 [52-62] years old) were randomized 3:2 to zoledronic acid versus placebo (randomized at baseline, zoledronic acid [175 cases], placebo-zoledronic acid [110 cases]). The bone mineral density of the lumbar spine and total hip was measured every 6 months with the use of dual-energy X-ray absorptiometry. Serum procollagen I N-terminal pro-peptide (PINP) and serum C-telopeptide of type I collagen (CTX) levels were measured every 6 months. The primary end point was the rate of change in the bone mineral density at the posteroanterior spine. RESULTS: For subjects with measurements at 24 months, zoledronic acid significantly increased bone mineral density (BMD) at the lumbar spine (mean percent change ± SD, zoledronic acid 5.390% ± 0.854% versus placebo-zoledronic acid -1.038% ± 0.599%), the total hip (zoledronic acid 1.900% ± 0.262% versus placebo-zoledronic acid -1.631% ± 0.649%). Serum procollagen I N-terminal pro-peptide (PINP) and CTX decreased rapidly with zoledronic acid 5 mg treatment (P < 0.001 versus placebo at 6 month and 24 months) and changed from baseline in the zoledronic acid 5 mg and placebo-zoledronic acid 5 mg at 6 months by a mean of -66.348% and -75.375%, respectively (P < 0.001), and at 24 months by -49.950% and -52.325%, respectively (P < 0.001). No cases of serious adverse events were observed in two groups. Headache, pyrexia and myalgia occurred more commonly within the first 3 days after infusion with zoledronic acid 5 mg than with placebo (13.7% versus 2.1%, P = 0.0018; 28.0% versus 3.2%, P < 0.001; 21.7% versus 4.2%, P < 0.001, respectively). CONCLUSIONS: These data show that early application of zoledronic acid 5 mg/year was well stimulated and tolerated for bone mass in newly diagnosed east china subjects with osteoporosis in a 24-month treatment. SN - 1757-7861 UR - https://www.unboundmedicine.com/medline/citation/28276638/Intravenous_Zoledronic_Acid_5_mg_on_Bone_Turnover_Markers_and_Bone_Mineral_Density_in_East_China_Subjects_with_Newly_Diagnosed_Osteoporosis:_A_24_month_Clinical_Study_ L2 - https://doi.org/10.1111/os.12307 DB - PRIME DP - Unbound Medicine ER -